Results 221 to 230 of about 102,788 (290)

Autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK: A 20‐year retrospective analysis of activity and haematological outcomes from the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT)

open access: yesBritish Journal of Haematology, EarlyView.
We report the UK experience of autologous haematopoietic stem cell transplantation (AHSCT) for multiple sclerosis (MS) in 364 patients. In our observational study, transplant‐related mortality was 1.4%, Epstein–Barr virus reactivation occurred in 75.9%, while disability progression‐free survival was 83.5% at 2 years post‐AHSCT and 62.4% at 5 years.
Majid Kazmi   +18 more
wiley   +1 more source

Secondary malignancies after chronic myeloid leukaemia upon TKI treatment: Population trends and outcomes

open access: yesBritish Journal of Haematology, EarlyView.
A retrospective study from 11 institutions was performed in 139 chronic myeloid leukaemia (CML) patients with secondary malignancies. The median ages at diagnosis of CML and secondary malignancy were 51 years (range, 13–88 years) and 53 years (range, 18–91 years). After a median follow‐up of 85 months, the median time from diagnosis of CML to secondary
Yingling Zu   +17 more
wiley   +1 more source

Outcomes of children with haematological malignancies given second haploidentical haematopoietic stem cell transplantation with either TCRαβ/CD19 depletion or post‐transplant cyclophosphamide

open access: yesBritish Journal of Haematology, EarlyView.
Summary Human leukocyte antigen (HLA)‐haploidentical haematopoietic cell transplantation (haplo‐HCT) is a suitable salvage strategy in children with haematological malignancies experiencing either relapse or graft failure (GF) after the first HCT.
Riccardo Masetti   +20 more
wiley   +1 more source

CD123‐targeting immunotherapeutic approaches in acute myeloid leukaemia

open access: yesBritish Journal of Haematology, EarlyView.
Summary Treatment of relapsed or refractory acute myeloid leukaemia (AML) has remained a significant challenge, with limited available targeted immunotherapies. CD123, or the interleukin‐3 (IL‐3) receptor, has long been known as a potential target expressed on AML blasts, and a range of different approaches to targeting CD123 have been trialled with ...
Alexandra Dreyzin   +2 more
wiley   +1 more source

The importance of systemic inflammatory response measurements as pretransplant risk factors for outcome after allogeneic haematopoietic cell transplantation

open access: yesBritish Journal of Haematology, EarlyView.
In oncological patients SIR measures like the mGPS have great impact on prognosis at starting therapy. We recorded at admission for allo‐HCT the mGPS in 2201 patients: score 0 CRP/sALB normal; score 1 CRP >10mg/dl; score 2 CRP >10mg/dl + sALB <35g/L. Multivariate analysis revealed a significant impact with a low GPS score for OS: mGPS 1 vs.
Hartmut Bertz   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy